Short answer
Adicet Bio Inc (ACET) filed an 8-K current report with the SEC on September 8, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item 7.01 (Regulation FD Disclosure). Adicet furnished an investor presentation on September 8, 2026, signaling a scheduled corporate or clinical update.
Adicet Bio Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Adicet furnished an investor presentation on September 8, 2026, signaling a scheduled corporate or clinical update
- Presentation available through Adicet’s investor website and Exhibit 99.1, requiring review for substantive pipeline developments
Item EX-99.1 · Exhibit EX-99.1
- Prula-cel positioned for autoimmune diseases, targeting LN, SLE and SSc with off-the-shelf, one-time outpatient dosing
- Early data from 7 patients showed clinical activity, including kidney-function improvement and immune reset, but remains small and early-stage
- ADI-212 IND cleared for mCRPC, with first-patient dosing targeted for 4Q26 and clinical data expected in 1H27 and 2H27
- In vivo CAR-T portfolio targets multiple myeloma, NHL and solid tumors, with first clinical entry expected in 2H27
- Near-term value depends on regulatory alignment, pivotal-study progression and financing capacity across multiple clinical programs
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Adicet Bio Inc 8-K filings
Get the next ACET 8-K as it lands
Follow ACET for push alerts, or ask the research agent what this filing means.